Next Article in Journal
Mushroom Polysaccharides as Potential Candidates for Alleviating Neurodegenerative Diseases
Previous Article in Journal
Ultra-Processed Foods and Drinks Consumption Is Associated with Psychosocial Functioning in Adolescents
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 14
Issue 22
10.3390/nu14224832
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Supplementation of Lactobacillus plantarum (TCI227) Prevented Potassium-Oxonate-Induced Hyperuricemia in Rats

by
Chih-Yu Chien
1,†,
Yu-Jou Chien
1,†,
Yung-Hao Lin
2,
Yung-Hsiang Lin
3,
Shu-Ting Chan
3,
Wei-Chun Hu
3,
Han-Fang Wu
3,
Chi-Fu Chiang
3 and
Chin-Lin Hsu
1,4,*
1
Department of Nutrition, Chung Shan Medical University, Taichung 40201, Taiwan
2
Baiyuete Limited Company, Shanghai 200071, China
3
Research & Design Center, TCI Co., Ltd., Taipei 11472, Taiwan
4
Department of Nutrition, Chung Shan Medical University Hospital, Taichung 40201, Taiwan
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Nutrients 2022, 14(22), 4832; https://doi.org/10.3390/nu14224832
Submission received: 30 September 2022 / Revised: 8 November 2022 / Accepted: 9 November 2022 / Published: 15 November 2022
(This article belongs to the Section Nutrition and Metabolism)
Browse Figures
Versions Notes

Abstract

:
Hyperuricemia (HC) is one of the important risk factors for gout, arteriosclerosis, and cardiovascular disease. Animal studies have shown that Lactobacillus plantarum can improve microbiota and immune regulation, as well as inhibit uric acid production. However, it is not clear whether L. plantarum can improve HC and intestinal microbiota. We used potassium oxonate (PO) to induce HC in male SD rats and then treated them with L. plantarum TCI227 in a dose-dependent manner (HC + LD, HC + MD, HC + HD) for 4 weeks. We examined organ weight, conducted biochemical examinations of blood and urine, and analyzed the intestinal microbiota in feces through a 16s rDNA sequence analysis. In this study, TCI227 improved body weight, decreased creatinine and serum uric acid, and increased urine uric acid compared to the HC group. Furthermore, TCI227 increased short-chain fatty acids (SCFAs). In the fecal microbiota (family), TCI227 increased the level of Lactobacillaceae and then decreased the levels of Deferribacteres and Prevotellaceae compared to the HC group. Finally, in the fecal microbiota (genus), TCI227 decreased the level of Prevotella and then increased the levels of Lactobacillus and Ruminococcus compared to the HC group. This study suggested that TCI227 can improve HC and can change the composition of intestinal microbiota in PO-induced male HC SD rats.

Graphical Abstract

1. Introduction

Uric acid (UA) is the final product of nucleic acid metabolism in the body [1]. Purine in the body is metabolized by the liver to form uric acid, and finally, the kidneys excrete uric acid from the body [2]. If too much UA is produced in the body or if it is poorly excreted by the kidneys, it forms crystals and that are deposited in the body, leading to hyperuricemia (HC), which is a chronic disease [3]. Risk factors include obesity, as well as the consumption of too much fructose, meat, or seafood [4]. HC patients are often accompanied by chronic diseases, such as gout, diabetes, heart disease, and kidney disease [5]. In addition to adjusting diet and weight control, the most direct way of treatment is drug intervention [6], but it has side effects, such as allergies, nephrotoxicity, liver toxicity, nausea, and vomiting, and most patients with HC are unable to achieve long-term control due to high-purine diets and poor treatment efficacy [7]. Therefore, in recent years, naturally derived dietary supplements are often used as preventive and adjuvant treatments for HC.
UA is secreted into the intestines and is rapidly metabolized by intestinal bacteria [8]. A study showed that the intestinal microbiota compositions of gout patients were significantly different compared to normouricemic subjects [8], suggesting that interaction among the microbiota, intestinal UA metabolism, and excretion can potentially modulate serum uric acid levels. A study also showed that changing the structure and amount of intestinal microbiota affected the metabolic rate of UA, thus reducing the UA content in the blood [9]. Furthermore, the transport protein of UA was found to be secreted by various indigenous microbes in the human gut [10]. Probiotic supplements have anti-uric acid, anti-inflammatory, immune regulation, and gastrointestinal barrier functions [11]. Therefore, the development of probiotic treatment strategies to reduce UA concentrations would be useful [11,12].
Probiotics are live microbial dietary supplements that exert beneficial effects on host health due to their potential effectiveness for the prevention and treatment of immune diseases [13]. Lactobacillus is the most common probiotic in the human body and is a kind of lactic acid bacteria. L. plantarum has a variety of potential beneficial effects on human health [14], such as improvement of the microbiota, immune regulation, suppression of fat accumulation, and reduction of serum triglycerides and cholesterol. Furthermore, L. plantarum treatment significantly reverses UA levels induced by a high-fat diet (HFD) and reduces the size of adipocytes [12,14]. However, it is still unclear whether L. plantarum can improve HC and intestinal microbiota.
Therefore, this study uses potassium oxonate (PO), a selectively competitive uricase inhibitor, to induce HC in rats [15] and then evaluates the effectiveness of L. plantarum TCI227 to improve HC and intestinal microbiota.

2. Materials and Methods

2.1. Animals and Ethics Statement

A total of forty-eight adult male SD rats (6 weeks old) were ordered for this study. All animals were kept in steel rodent cages, and the animal room temperature was controlled at 22 ± 2 °C. The humidity was controlled at 60–80%, with a 12 h light:dark cycle (light period: 07:00–19:00; dark period: 19:00–07:00). The animal use protocol listed below was reviewed and approved by the Chung Shan Medical University Institutional Animal Care and Use Committee (IACUC approval no: 2413). All animals were fed regular formula feed and distilled water until 8 weeks old; then, the test sample started the intervention.

2.2. Design of Animal Experiments

Forty-eight Wistar SD (Sprague–Dawley) rats were randomly assigned to 6 groups of 8 animals each. The control group was injected intraperitoneally with vehicle, while the others were injected intraperitoneally with a potassium oxonate suspension (Sigma-Aldrich, Schelldorf, Germany) of 250 mg/kg for hyperuricemia induction every day for 4 consecutive weeks. Test samples were administered during the hyperuricemia induction phenotype. The six groups were divided into: (a) the normal control group (control, C); (b) the hyperuricemia control group (hyperuricemia control, HC); (c) the low dose (108 CFU/kg rat/day) of TCI227 oral gavage treatment hyperuricemia-induced group (low dose, LD) (HC + LD); (d) the medium dose (109 CFU/kg rat/day) of TCI227 oral gavage treatment hyperuricemia-induced group (medium dose, MD) (HC + MD); (e) the high dose (1010 CFU/kg rat/day) of TCI227 oral gavage treatment hyperuricemia-induced group (high dose, HD) (HC + HD); and (f) the allopurinol (10 mg/kg rat/day) treatment hyperuricemia-induced group (HC + AP). From day 0 to day 28, the rats in groups (b)–(f) were treated once daily with PO, and those in groups (c)–(f) were treated with oral gavage of different doses of TCI227 and allopurinol. All animals were euthanized on day 28. On day 21, stool samples were collected from animals and kept in RNA stabilizer reagent (Cat. No. MLBRS0500, Taichung City, Taiwan) until day 28. The rats were fasted for 8–12 h before blood samples were collected to measure additional serum biochemical parameters from the tail veins prior to euthanization. Meanwhile, organ tissues, including heart, lung, liver, spleen, kidney, and adipose tissues (perirenal fat, epididymal fat, subcutaneous fat, mesenteric fat, and brown adipose tissue), as well as muscle tissues (gastrocnemius and soleus), were removed using PBS wash, and the weight was recorded prior to freezing with liquid nitrogen and storage at −80 °C.

2.3. Chemicals

Potassium oxonate (PO), allopurinol, and oxonic acid (potassium salt) were purchased from Sigma-Aldrich Chemie GmbH (Schnelldorf, Germany). L. plantarum powder (TCI227) was prepared by TCI Co. Ltd. A uric acid assay kit was purchased from Abcam (Cambridge, UK). Sodium chloride (NaCl) was purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Formalin (HCHO) was purchased from Choneye Co., Ltd. (New Taipei City, Taiwan).

2.4. Serum Biochemical Parameter Analysis

Blood was collected in a serum separator tube (BD Vacutainer, Plymouth, UK) and centrifuged at 3000× g for 15 min, and then serum supernatant was transferred to the tube and stored at −80 °C for analysis. The levels of serum aspartate transaminase (AST), alanine transaminase (ALT), creatinine, blood urea nitrogen (BUN), triglycerides, total cholesterol, sodium ions (Na+), potassium ion concentration (K+), and chloride ions (Cl−) were analyzed with a fully automatic biochemical immunoassay analyzer (C501, Roche, Basel, Switzerland).

2.5. Uric Acid Content of Serum and Urine Analysis

Before the chemical intervention, blood samples were collected as control at week 0. Four weeks after intervention, blood samples were also collected for analysis. The blood was centrifuged at 3000× g for 15 min, and serum was taken out for analysis. Before the chemical intervention (week 0), as well as at the second and fourth weeks of the intervention, the rats were placed in a metabolic cage for 24 h, and their urine was collected in a centrifuge tube. Subsequently, the urine was centrifuged at 3000× g for 10 min at 4 °C, and the supernatant was collected. The levels of uric acid in the serum and urine were measured with a commercially available analysis kit (Abcam, Cambridge, UK).

2.6. Analysis of Short-Chain Fatty Acid Composition in Feces

A weight of 0.5 g of rat feces was added to 5 mL deionized water, homogenized for 2 min, and centrifuged at 7000 rpm for 5 min at 25 °C, and the supernatant was filtered. An amount of 1 mL supernatant was added to internal standard isocaproic acid, 100 μL 50% (v/v) sulfuric acid solution, and 1 mL of ether and homogenized for 2 min and centrifuged at 4000 rpm for 5 min at 25 °C. The supernatant was extracted. Then, it was further analyzed by gas chromatography (6890, Agilent Technologies, Santa Clara, CA, USA) for the contents of acetic acid, propionic acid, butyric acid, and valeric acid in the stool.

2.7. Stool DNA Purification and Next-Generation Sequencing for Intestinal Microbiota Analysis

The fecal nucleic acid extraction was purified using a QIAamp Fast DNA Stool Mini Kit to extract nucleic acid from bacteria in feces. Fecal samples were removed from the preservation solution at 13,200 rpm for 10 min. Feces were shaken and dissolved by adding InhibitEX buffer, and subsequent reagents were added in sequence. The supernatant was then collected and washed by transfer into a QIAmp spin column. Finally, preheated elution buffer was used for the elution of the DNA. A NanoDrop 2000 was used for concentration determination. Then, a next-generation sequence was used for further microbiota identification. The Illumina 16S Metagenomic Sequencing Library Preparation Manual Protocol was performed for intestinal microbiota analysis. The V3 and V4 gene fragments of bacterial 16S rRNA were amplified to develop amplicon libraries, and we further sequenced paired ends with Illumina MiSeq. A V3 MiSeq reagent kit (600 cycles) was used, with a sequencing quality of Q30 ≥ 80% and a single sample ≥100,000 reads.

2.8. Statistical Analyses

The experimental data were analyzed using Statistical Product and Service Solutions (SPSS), version 22.0. Variance analysis was performed using Student’s t-test with unpaired individuals, and the experimental data were presented as means ±SD, with a p-value < 0.05 considered statistically significant.

3. Results

3.1. TCI227 Improved Body Weight and Diet in PO-Induced HC Rats

To evaluate whether TCI227 improved HC and intestinal microflora, we used potassium oxonate (PO) (250 mg/kg, intraperitoneal injection) to induce HC in SD rats and then treated them with TCI227 in a dose-dependent manner (LD, MD, and HD) by oral administration for 4 weeks. Allopurinol can be used as an antihyperuricemia drug [16]. The detailed process is showed in Figure A1. We examined body weight and diet in PO-induced HC rats. Table 1 shows that there were no significant differences in initial body weight (week 0). However, the final weight (week 4) of the HC group was significantly decreased compared to that of the control group. Furthermore, the weight change in the HC group was significantly decreased compared with the control group, while the HC + MD and HC + HD groups were significantly increased compared with the HC group. The food intake of the HC group was significantly decreased compared with the control group, and the HC + LD, HC + MD, and HC + HD groups were significantly increased compared with the HC group. Water intake in the HC group was significantly decreased compared to the control group, and the HC + HD and HC + AP groups were significantly increased compared to the HC group. We also examined organ weight, adipose tissue weight, and muscle tissue weight in PO-induced HC rats.
Table 2 shows that the weights of the liver and spleen for the HC group were significantly increased compared to the control group in week 4, and the weight of the perirenal adipose tissue for the HC group was significantly decreased compared to the control group in week 4. There were no obvious changes in other organs and tissues. These results indicate that treatment with TCI227 could improve body weight and diet in PO-induced HC rats.

3.2. TCI227 Improved Hyperuricemia and Did Not Affect Liver and Kidney Function

Next, we examined blood and urine in PO-induced HC rats in week 4. Table 3 shows that there were no statistical differences between the groups in glucose, total cholesterol, AST, ALT, BUN, and potassium. Triglyceride and sodium ions in the HC group decreased significantly compared to the control group, and triglyceride in the HC + AP group decreased significantly compared to the HC group. Creatinine in the HC + MD group decreased significantly compared to the HC group, and chloride ions in the HC group increased significantly compared to the control group.
In addition, Table 4 shows that serum uric acid level in the HC group increased in week 4, while those of the HC + LD, HC + MD, and HC + AP groups decreased significantly compared to the HC group. The urine uric acid level in the HC group was decreased compared to the HC group in weeks 2 and 4, and those of the HC + LD and HC + MD groups were significantly increased compared to the HC group in week 4 and weeks 2 and 4, respectively. These results suggest that the administration of low (108 CFU/kg/rat) and medium (109 CFU/kg/rat) doses of TCI227 could decrease serum uric acid and increase urine uric acid, as well as that TCI227 did not influence liver and kidney function.

3.3. TCI227 Increased SCFAs and Diversity of Intestinal Microbiota

Studies had shown that intestinal bacteria can use dietary fiber to ferment into short-chain fatty acids (SCFAs), such as acetic acid, propionic acid, butyric acid, and valeric acid [17]. SCFAs can provide energy for intestine cells, maintain intestinal mucosa integrity, inhibit harmful bacteria, and promote the growth of beneficial bacteria [18]. Next, we examined fecal SCFAs in PO-induced HC rats. Table 5 shows that acetic acid, butyric acid, and valeric acid levels in the HC group were significantly decreased compared to the control group. SCFAs in the HC + LD, HC + MD, and HC + HD groups were increased more than those in the HC group. Then, we examined the diversity of the intestinal microbiota, and Shannon’s diversity index was used to estimate the level of community diversity [19].
Figure 1 shows that the Shannon’s diversity index value for the HC group decreased slightly compared to the control group, and those of the HC + LD and HC + MD groups increased slightly compared to the HC group. Through a principal coordinates analysis (Figure 2), we found a significant difference between the HC group and the control group in microbiota composition and also found significant differences between the HC + LD, HC + MD, and HC + HD groups and the HC group. These results show that HC reduced SCFAs and the diversity of intestinal microbiota and that TCI227 could recover this phenomenon and regulate the composition of the microbiota.

3.4. TCI227 Changed Composition of Intestinal Microbiota

Next, we wanted to explore whether TCI227 could change the composition of intestinal microbiota using 16S microbiota ribosomal DNA sequencing. The eight most abundant fecal microbiota phylum of the CTL, HC, HC + LD, HC + MD, HC + HD, and HC + AP groups are shown (Figure 3). The most abundant microbiota (phylum) were Firmicutes and Bacteroridetes. When the ratio of Firmicutes/Bacteroidetes or the number of Deferribacteres are increased, it can promote obesity or gout in mice [20,21]. Figure 4 shows that the relative abundance of Deferribacteres in the HC group was significantly increased compared to the control group, while the HC+MD and HC+HD groups showed significantly decreased relative abundances of Deferribacteres compared to the HC group.
In addition, the top 30 most abundant fecal microbiota families of the CTL, HC, HC + LD, HC + MD, HC + HD, and HC + AP groups are also shown (Figure 5). The most abundant microbiota (families) were Muribaculaceaec and Ruminococcaceae. Figure 6 shows that the relative abundance of Prevotellaceae in the HC group was significantly increased compared to the control group, and that of the HC + MD group was significantly decreased compared to the HC group. In addition, the relative abundance of Lactobacillaceae in the HC group decreased compared to the control group, and that of the HC + HD group was significantly increased. The relative abundance of Deferribacteraceae in the HC group was increased compared to the HC group, and those of the HC + MD and HC + HD groups were significantly decreased.
The major HC relative abundant fecal microbiota genera were Prevotella, Oscillibacter, and Ruminococcus (Figure 7). Figure 8 shows that the relative abundance of Prevotella in the HC group increased significantly compared to the control group, and that of the HC + MD group significantly decreased in abundance. The relative abundance of Lactobacillus in the HC group decreased in comparison to the control group, and that of the HC + HD group significantly increased in abundance. Moreover, the relative abundance of Ruminococcus in the HC group was significantly decreased compared to the control group, and those of the HC + LD and HC + MD groups were significantly increased in abundance. The above results indicate that TCI227 could change the composition of the intestinal microbiota.

4. Discussion

Most mammals contain uricase, which can metabolize uric acid as allantoin. However, several primates, including humans, have lost the function of uricase enzyme activity. It has been reported that uricase genes display two stop codons and act as a pseudogenes in human [22,23]. Without the metabolic ability of uric acid, elevated uric acid levels can cause the accumulation of urate crystals and lead to gout and gouty arthritis. In addition, hyperuricemia is associated with other metabolic diseases, including hyperlipidemia, hypertension, cardiovascular diseases, and diabetes [24]. In the past, antihyperuricemia drugs have been identified, including xanthine oxidase (XOD) inhibitors (allopurinol and febuxostat) and uricosuric agents (benzbromarone and probenecid), in clinical practice. Unfortunately, side effects limit the use of these drugs for hyperuricemia treatment [25,26]. Therefore, in this study, uricase inhibition modeled on potassium-oxonate-treated rats [27] was performed with a TCI227 probiotics intervention to investigate a new, improved strategy of hyperuricemia treatment.
A previous study showed that the body weight of a PO-induced hyperuricemia mouse model was significantly lower than that of control rats [28], which is similar to Table 1 of this study. More precisely, not only body weight, but also the results of food intake and water consumption records, were still within the physiological ranges of normal rats [29,30]. In the organ weight results of Table 2, the livers and spleens of PO-induced rats were significantly heavier than those of the control group (p < 0.05), and the weight of the perirenal fat tissue of PO-induced rats was significantly lighter than that of the control group (p < 0.05). We speculated two reasons for the increase in organ weight. First, the results of the histological section of the study revealed some necrosis in the peritoneal fat and an inflammation phenomenon after the intraperitoneal injection of PO (data not shown), which were probably associated with the formation of urate and could lead to foreign bodies, necrosis, and chronic granulomatous lesions. Second, the literature suggests that, when an organ develops a disease, the abundance of macrophages also increases [31]. Hence, after PO induced a hyperuricemia phenotype in the rats, an increase in the macrophages of organs could result in an increase in organ weight.
Regarding the toxicity test, a serum biochemical parameter analysis was performed, as shown in Table 3. The concentrations of serum triglycerides, creatinine, sodium ions, and chloride ions in the hyperuricemia groups were significantly different compared to the control group (p < 0.05). All of these chemical parameters were within the physiological ranges of normal rats in other research [32,33]. In brief, the TCI227 intervention did not cause liver injury, renal dysfunction, or electrolyte dysregulation. This evidence suggests that the TCI227 could be used as a safe oral health food to ameliorate hyperuricemia.
According to Table 4, the low and medium doses of the TCI227 intervention could significantly reduce the serum uric acid concentrations of hyperuricemia rats (p < 0.05). Previous literature reports have also suggested that oral gavage probiotics of Lactobacillus (1.5 × 109 CFU/mL/day) from kimchi or ursolic acid (5 and 10 mg/kg) can improve blood uric acid concentrations in PO-induced hyperuricemia rats [34,35]. Another study showed that, in PO-induced hyperuricemia mice, supplementation with Prunus mume fruit extract (140 mg/kg) for 1 week could increase urine uric acid excretion in mice [36]. This evidence suggests that supplementation with natural dietary supplements has the effect of ameliorating hyperuricemia.
Recently, many chronic diseases (e.g., obesity, diabetes, and nonalcoholic fatty liver disease) have been associated with unbalanced dysregulation of intestinal flora-mediated inflammation [37]. A previous study indicated that hyperuricemia rats with high levels of long-term urate concentration in the blood had increased production of reactive oxygen species, leading to activated NF-κB or other responses from inflammation pathways. Subsequently, it promoted the expressions of inflammation factors IL-1β and TNF-α, causing immune dysfunction and leaky gut syndrome, followed by exaggerated immune response and intestinal barrier dysfunction, which triggered hyperuricemia progression [34,38].
A decrease in gut microbial diversity is always accompanied by an abnormal decrease in bacterial flora decrement and is associated with most human diseases [39]. Some studies have suggested that supplement intake has the effect of elevated microbial diversity. Figure 1 shows that PO-induced hyperuricemia rats had reduced abundances and α-diversity of the gut microbiota using Shannon’s diversity index analysis (p > 0.05). Medium and low doses of TCI227 intervention could slightly increase the Shannon’s diversity index values and improve the decrease in microbiota diversity decrement (p > 0.05). Although this result was not significant, the trend was very similar to a previous PO-induced hyperuricemia Kunming mice microbiota analysis. In that study, after a Lactobacillus fermentum JL-3 intervention, inflammatory markers and indicators of oxidative stress (IL-1β, MDA, CRE, and blood urea nitrogen) related to hyperuricemia were improved and microbial diversity was increased. Notably, another study showed that an allopurinol intervention did not significantly improve the diversity of gut flora (p > 0.05) in induced hyperuricemia SD rats on a high-fat diet containing 10% yeast extract, which is very similar to our results in Figure 1 [40].
In the analysis of the composition of microbiota phylum, Figure 4 suggests that the abundances of Deferribacteres were increased in PO-induced hyperuricemia rat fecal matter. According to a previous publication, an abundance of Deferribacteres was positively correlated with the concentration of IL-6 in plasma [41]. The pro-inflammatory factor IL-6 plays a crucial role in chronic inflammation diseases. Furthermore, past research showed that PO-induced hyperuricemia rats (250 mg/kg, rats) could display increases in IL-6 and other inflammation indicators [42]. In this study, the PO-induced hyperuricemia groups had higher abundances of Deferribacteres (p < 0.05). The medium and high doses of the TCI227 intervention significantly reversed the abundance of Deferribacteres (p < 0.05). Deferribacteres is correlated with immune response, which is positively associated with the levels of IL-6, IL-2, and TNF-α in serum. In a mouse model of sepsis treated with Lactobacillus rhamnosus GG (2 × 109 CFU/mL) intestinal permeability and microbiota dysbiosis were improved. In that study, the abundance of Deferribacteraceae was reduced after Lactobacillus rhamnosus GG treatment [43]. In the microbiota family composition analysis, our results were similar to another group’s findings [44]. An intestinal dysbiosis phenomenon was observed in hyperuricemia-induced rats. The abundance of Prevotellaceae was increased in Figure 6, which is significantly similar to the TCI227 intervention in this study (p < 0.05). Furthermore, the abundance of Lactobacillaceae was reduced, which corresponds to an ICR mouse oral gavage of PO at 250 mg/kg from another group [45]. In our analysis of the composition of microbiota genera, the abundance of Prevotella, which is associated with chronic inflammation, significantly increased in hyperuricemia rats (p < 0.05). The intervention of TCI227 could significantly reverse the abundance of Prevotella (p < 0.05), as shown in Figure 7. According to a previous study [44], the abundances of Lactobacillaceae and Rumminococcus were decreased in hyperuricemia mice. Another study also suggested that the abundance of Rumminococcus decreased in mice inactivated with uricase [46]. Our results suggest that the abundances of Lactobacillaceae and Rumminococcus in hyperuricemia rats were lower than those of the control (p < 0.05), and this phenomenon was reversed by the TCI227 intervention. Lactobacillaceae and Rumminococcus can produce short-chain fatty acids (SCFAs), which can ameliorate kidney function. Hence, the increase in the abundances of Lactobacillaceae and Rumminococcus was facilitated by uric acid metabolism, and the intake of TCI227 could improve hyperuricemia.
A previous study suggested that intestinal microbiota could participate in purine and uric acid metabolism. On the other hand, SCFAs not only provided an energy resource for enterocytes, but also facilitated mucus secretion [47]. These bacterial fermentation products may play an important role in the mucoprotection of gut health by supporting the integrity of the mucosal barrier and preventing systemic inflammatory response. In hyperuricemia rats, less bacterial abundance of SCFA production was observed, including Alistipes, Lactobacillus, and Ruminococcus, resulting in low SCFA concentrations mediating intestinal barrier dysfunction and increasing intestinal permeability. In Table 5, the acetic acid, butyric acid, and valeric acid levels in the HC group were significantly lower than in the control group. After the TCI227 intervention, these SCFA contents were significantly increased (p < 0.05). No significant increase in SCFAs by the AP cotreatment group was derived due to the differently regulated mechanisms of AP and TCI227 in the amelioration of hyperuricemia.

5. Conclusions

Supplementation with TCI227 (low and medium doses of 108 and 109 CFU/kg rat, respectively) could ameliorate the concentration of uric acid in serum and the excretion of uric acid in urine in PO-induced hyperuricemia rats. In addition, administration of the TCI227 not only increased the abundance of intestinal microbiota, but also increased the concentrations of acetic acid, butyric acid, and valeric acid in PO-induced hyperuricemia rats. All these studies demonstrated that the administration of TCI227 improved hyperuricemia rats induced with potassium oxonate (PO).

Author Contributions

C.-L.H., Y.-H.L. (Yung-Hao Lin) and Y.-H.L. (Yung-Hsiang Lin), designed the experiments; C.-Y.C., Y.-J.C., S.-T.C., W.-C.H., H.-F.W. and C.-F.C. carried out the laboratory experiments; C.-L.H., C.-Y.C., Y.-J.C., S.-T.C., W.-C.H., H.-F.W. and C.-F.C. analyzed the data, interpreted the results, prepared the figures, and wrote the manuscript; C.-L.H., Y.-J.C., Y.-H.L. (Yung-Hao Lin) and Y.-H.L. (Yung-Hsiang Lin) revised the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This study was sponsored by a grant from TCI CO., Ltd. (No. 187 Gangchang Road, Neihu District, Taipei 11472, Taiwan).

Institutional Review Board Statement

The animal study protocol was approved by the Institutional Review Board (or Ethics Committee) of the Chung Shan Medical University Institutional Animal Care and Use Committee (IACUC approval no: 2413 and date of approval).

Informed Consent Statement

Not applicable.

Data Availability Statement

The datasets analyzed or generated during this study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare no conflict of interest.

Appendix A

Nutrients 14 04832 g0a1 550
Figure A1. Schematic of probiotic-prevented hyperuricemia progression model.
Figure A1. Schematic of probiotic-prevented hyperuricemia progression model.
Nutrients 14 04832 g0a1

References

  1. Akram, M.; Asghar, M.N.; Saleem Khan, M.; Shahid, S.; Abdur Rahman, H.M.; Nadeem, I. Development and validation of an economical uric acid-Fe(3+)/Fe(2+)-ferrozine-based colorimetric assay to estimate uric acid level of pure and biological samples. Biosci. Biotechnol. Biochem. 2020, 84, 1967–1974. [Google Scholar] [CrossRef] [PubMed]
  2. Trinchieri, A.; Montanari, E. Biochemical and dietary factors of uric acid stone formation. Urolithiasis 2018, 46, 167–172. [Google Scholar] [CrossRef] [PubMed]
  3. Mandal, A.K.; Mount, D.B. The molecular physiology of uric acid homeostasis. Annu. Rev. Physiol. 2015, 77, 323–345. [Google Scholar] [CrossRef] [PubMed]
  4. Bardin, T.; Richette, P. Definition of hyperuricemia and gouty conditions. Curr. Opin. Rheumatol. 2014, 26, 186–191. [Google Scholar] [CrossRef]
  5. Torralba, K.D.; De Jesus, E.; Rachabattula, S. The interplay between diet, urate transporters and the risk for gout and hyperuricemia: Current and future directions. Int. J. Rheum. Dis. 2012, 15, 499–506. [Google Scholar] [CrossRef]
  6. Ben Salem, C.; Slim, R.; Fathallah, N.; Hmouda, H. Drug-induced hyperuricaemia and gout. Rheumatology 2017, 56, 679–688. [Google Scholar] [CrossRef] [Green Version]
  7. Kubota, M. Hyperuricemia in Children and Adolescents: Present Knowledge and Future Directions. J. Nutr. Metab. 2019, 2019, 3480718. [Google Scholar] [CrossRef]
  8. Guo, Z.; Zhang, J.; Wang, Z.; Ang, K.Y.; Huang, S.; Hou, Q.; Su, X.; Qiao, J.; Zheng, Y.; Wang, L.; et al. Intestinal Microbiota Distinguish Gout Patients from Healthy Humans. Sci. Rep. 2016, 6, 20602. [Google Scholar] [CrossRef] [Green Version]
  9. Wong, J.; Piceno, Y.M.; DeSantis, T.Z.; Pahl, M.; Andersen, G.L.; Vaziri, N.D. Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am. J. Nephrol. 2014, 39, 230–237. [Google Scholar] [CrossRef] [Green Version]
  10. Hosomi, A.; Nakanishi, T.; Fujita, T.; Tamai, I. Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2. PLoS ONE 2012, 7, e30456. [Google Scholar] [CrossRef]
  11. Andres, M.; Sivera, F.; Falzon, L.; Buchbinder, R.; Carmona, L. Dietary supplements for chronic gout. Cochrane. Database Syst. Rev. 2014, 10, CD010156. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Hsu, C.L.; Hou, Y.H.; Wang, C.S.; Lin, S.W.; Jhou, B.Y.; Chen, C.C.; Chen, Y.L. Antiobesity and Uric Acid-Lowering Effect of Lactobacillus plantarum GKM3 in High-Fat-Diet-Induced Obese Rats. J. Am. Coll. Nutr. 2019, 38, 623–632. [Google Scholar] [CrossRef] [PubMed]
  13. Kim, S.K.; Guevarra, R.B.; Kim, Y.T.; Kwon, J.; Kim, H.; Cho, J.H.; Kim, H.B.; Lee, J.H. Role of Probiotics in Human Gut Microbiome-Associated Diseases. J. Microbiol. Biotechnol. 2019, 29, 1335–1340. [Google Scholar] [CrossRef] [PubMed]
  14. Xiao, Y.; Zhang, C.; Zeng, X.; Yuan, Z. Microecological treatment of hyperuricemia using Lactobacillus from pickles. BMC Microbiol. 2020, 20, 195. [Google Scholar] [CrossRef]
  15. Hongyan, L.; Suling, W.; Weina, Z.; Yajie, Z.; Jie, R. Antihyperuricemic effect of liquiritigenin in potassium oxonate-induced hyperuricemic rats. Biomed. Pharm. 2016, 84, 1930–1936. [Google Scholar] [CrossRef]
  16. White, W.B.; Saag, K.G.; Becker, M.A.; Borer, J.S.; Gorelick, P.B.; Whelton, A.; Hunt, B.; Castillo, M.; Gunawardhana, L.; Investigators, C. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N. Engl. J. Med. 2018, 378, 1200–1210. [Google Scholar] [CrossRef]
  17. Morrison, D.J.; Preston, T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes 2016, 7, 189–200. [Google Scholar] [CrossRef] [Green Version]
  18. Li, L.; Ma, L.; Fu, P. Gut microbiota-derived short-chain fatty acids and kidney diseases. Drug Des. Devel. Ther. 2017, 11, 3531–3542. [Google Scholar] [CrossRef] [Green Version]
  19. Jiang, H.; Ling, Z.; Zhang, Y.; Mao, H.; Ma, Z.; Yin, Y.; Wang, W.; Tang, W.; Tan, Z.; Shi, J.; et al. Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav. Immun. 2015, 48, 186–194. [Google Scholar] [CrossRef] [Green Version]
  20. Indiani, C.; Rizzardi, K.F.; Castelo, P.M.; Ferraz, L.F.C.; Darrieux, M.; Parisotto, T.M. Childhood Obesity and Firmicutes/Bacteroidetes Ratio in the Gut Microbiota: A Systematic Review. Child. Obes. 2018, 14, 501–509. [Google Scholar] [CrossRef]
  21. Zhong, Y.; Nyman, M.; Fak, F. Modulation of gut microbiota in rats fed high-fat diets by processing whole-grain barley to barley malt. Mol. Nutr. Food Res. 2015, 59, 2066–2076. [Google Scholar] [CrossRef] [PubMed]
  22. Chang, B.S. Ancient insights into uric acid metabolism in primates. Proc. Natl. Acad. Sci. USA 2014, 111, 3657–3658. [Google Scholar] [CrossRef] [Green Version]
  23. Kratzer, J.T.; Lanaspa, M.A.; Murphy, M.N.; Cicerchi, C.; Graves, C.L.; Tipton, P.A.; Ortlund, E.A.; Johnson, R.J.; Gaucher, E.A. Evolutionary history and metabolic insights of ancient mammalian uricases. Proc. Natl. Acad. Sci. USA 2014, 111, 3763–3768. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Dalbeth, N.; So, A. Hyperuricaemia and gout: State of the art and future perspectives. Ann. Rheum. Dis. 2010, 69, 1738. [Google Scholar] [CrossRef] [PubMed]
  25. Pacher, P.; Nivorozhkin, A.; Szabó, C. Therapeutic Effects of Xanthine Oxidase Inhibitors: Renaissance Half a Century after the Discovery of Allopurinol. Pharmacol. Rev. 2006, 58, 87. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Hao, S.; Zhang, C.; Song, H. Natural Products Improving Hyperuricemia with Hepatorenal Dual Effects. Evid. Based Complement. Altern. Med. Ecam 2016, 2016, 7390504. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Sarvaiya, V.N.; Sadariya, K.A.; Pancha, P.G.; Thaker, A.M.; Patel, A.C.; Prajapati, A.S. Evaluation of antigout activity of Phyllanthus emblica fruit extracts on potassium oxonate-induced gout rat model. Vet. World 2015, 8, 1230–1236. [Google Scholar] [CrossRef] [Green Version]
  28. Shi, H.; Liang, X.S.; Huang, L.W.; Luo, Z.G.; Tan, L. The optimization and assessment of the method for inducing hyperuricemia in rats. Chin. J. Appl. Physiol. 2020, 36, 223–227. [Google Scholar] [CrossRef]
  29. Piao, Y.; Liu, Y.; Xie, X. Change trends of organ weight background data in sprague dawley rats at different ages. J. Toxicol. Pathol. 2013, 26, 29–34. [Google Scholar] [CrossRef] [Green Version]
  30. Křížova, E.; Imek, V.S.; Abelenda, M.; Puerta, M. Food intake and body weight in rats with daily food-availability restrictions. Physiol. Behav. 1996, 60, 791–794. [Google Scholar] [CrossRef]
  31. Sica, A.; Erreni, M.; Allavena, P.; Porta, C. Macrophage polarization in pathology. Cell. Mol. Life Sci. 2015, 72, 4111–4126. [Google Scholar] [CrossRef] [PubMed]
  32. Lee, J.M.; Lee, M.A.; Do, H.N.; Song, Y.I.; Bae, R.J.; Lee, H.Y.; Park, S.H.; Kang, J.S.; Kang, J.K. Historical control data from 13-week repeated toxicity studies in Crj:CD (SD) rats. Lab. Anim. Res. 2012, 28, 115–121. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Abubakar, S.; Sule, M. Effect of oral administration of aqueous extract of cassia occidentalis l. seeds on serum electrolytes concentration in rats. Bayero J. Pure Appl. Sci. 2010, 3, 183–187. [Google Scholar] [CrossRef] [Green Version]
  34. Lv, Q.; Xu, D.; Zhang, X.; Yang, X.; Zhao, P.; Cui, X.; Liu, X.; Yang, W.; Yang, G.; Xing, S. Association of Hyperuricemia With Immune Disorders and Intestinal Barrier Dysfunction. Front. Physiol. 2020, 11, 524236. [Google Scholar] [CrossRef] [PubMed]
  35. Abu-Gharbieh, E.; Shehab, N.G.; Almasri, I.M.; Bustanji, Y. Antihyperuricemic and xanthine oxidase inhibitory activities of Tribulus arabicus and its isolated compound, ursolic acid: In vitro and in vivo investigation and docking simulations. PLoS ONE 2018, 13, e0202572. [Google Scholar] [CrossRef] [Green Version]
  36. Yi, L.-T.; Li, J.; Su, D.-X.; Dong, J.-F.; Li, C.-F. Hypouricemic effect of the methanol extract from Prunus mume fruit in mice. Pharm. Biol. 2012, 50, 1423–1427. [Google Scholar] [CrossRef]
  37. Zmora, N.; Bashiardes, S.; Levy, M.; Elinav, E. The Role of the Immune System in Metabolic Health and Disease. Cell Metab. 2017, 25, 506–521. [Google Scholar] [CrossRef] [Green Version]
  38. Ma, C.; Yang, X.; Lv, Q.; Yan, Z.; Chen, Z.; Xu, D.; Liu, X.; Yang, W.; Xing, S. Soluble uric acid induces inflammation via TLR4/NLRP3 pathway in intestinal epithelial cells. Iran. J. Basic Med. Sci. 2020, 23, 744–750. [Google Scholar] [CrossRef]
  39. Mosca, A.; Leclerc, M.; Hugot, J.P. Gut Microbiota Diversity and Human Diseases: Should We Reintroduce Key Predators in Our Ecosystem? Front. Microbiol. 2016, 7, 455. [Google Scholar] [CrossRef] [Green Version]
  40. Yu, Y.; Liu, Q.; Li, H.; Wen, C.; He, Z. Alterations of the Gut Microbiome Associated With the Treatment of Hyperuricaemia in Male Rats. Front. Microbiol. 2018, 9, 2233. [Google Scholar] [CrossRef]
  41. Li, K.; Zhang, L.; Xue, J.; Yang, X.; Dong, X.; Sha, L.; Lei, H.; Zhang, X.; Zhu, L.; Wang, Z.; et al. Dietary inulin alleviates diverse stages of type 2 diabetes mellitus via anti-inflammation and modulating gut microbiota in db/db mice. Food Funct. 2019, 10, 1915–1927. [Google Scholar] [CrossRef] [PubMed]
  42. Chen, R.J.; Chen, M.H.; Chen, Y.L.; Hsiao, C.M.; Chen, H.M.; Chen, S.J.; Wu, M.D.; Yech, Y.J.; Yuan, G.F.; Wang, Y.J. Evaluating the urate-lowering effects of different microbial fermented extracts in hyperuricemic models accompanied with a safety study. J. Food Drug Anal. 2017, 25, 597–606. [Google Scholar] [CrossRef] [PubMed]
  43. Chen, L.; Li, H.; Li, J.; Chen, Y.; Yang, Y. Lactobacillus rhamnosus GG treatment improves intestinal permeability and modulates microbiota dysbiosis in an experimental model of sepsis. Int. J. Mol. Med. 2019, 43, 1139–1148. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Xu, D.; Lv, Q.; Wang, X.; Cui, X.; Zhao, P.; Yang, X.; Liu, X.; Yang, W.; Yang, G.; Wang, G.; et al. Hyperuricemia is associated with impaired intestinal permeability in mice. Am. J. Physiology. Gastrointest. Liver Physiol. 2019, 317, G484–G492. [Google Scholar] [CrossRef]
  45. Han, J.; Wang, X.; Tang, S.; Lu, C.; Wan, H.; Zhou, J.; Li, Y.; Ming, T.; Wang, Z.J.; Su, X. Protective effects of tuna meat oligopeptides (TMOP) supplementation on hyperuricemia and associated renal inflammation mediated by gut microbiota. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2020, 34, 5061–5076. [Google Scholar] [CrossRef] [Green Version]
  46. Guo, Y.; Yu, Y.; Li, H.; Ding, X.; Li, X.; Jing, X.; Chen, J.; Liu, G.; Lin, Y.; Jiang, C.; et al. Inulin supplementation ameliorates hyperuricemia and modulates gut microbiota in Uox-knockout mice. Eur. J. Nutr. 2021, 60, 2217–2230. [Google Scholar] [CrossRef]
  47. Willemsen, L.E.M.; Koetsier, M.A.; van Deventer, S.J.H.; van Tol, E.A.F. Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E(1) and E(2) production by intestinal myofibroblasts. Gut 2003, 52, 1442–1447. [Google Scholar] [CrossRef]
Nutrients 14 04832 g001 550
Figure 1. Alpha-diversity indices of richness of fecal microbiota compositions in rats with PO-induced hyperuricemia treated with TCI227. The Shannon index shows species richness and evenness. The reported values are means ± SD (n = 3). Significant difference among all the groups was not detected.
Figure 1. Alpha-diversity indices of richness of fecal microbiota compositions in rats with PO-induced hyperuricemia treated with TCI227. The Shannon index shows species richness and evenness. The reported values are means ± SD (n = 3). Significant difference among all the groups was not detected.
Nutrients 14 04832 g001
Nutrients 14 04832 g002 550
Figure 2. Effect of TCI227 on principal coordinates analysis (PCoA) index levels of fecal microbiota in rats with PO−induced hyperuricemia based on unweighted Jensen−Shannon distance measures of all samples based on OTU−level relative abundance profiles. Results are means for n = 3; # mean values are significantly different from control group (p < 0.05); * mean values are significantly different from HC group (p < 0.05) (Jensen−Shannon, genus, exclude unclassified OTU (reads)).
Figure 2. Effect of TCI227 on principal coordinates analysis (PCoA) index levels of fecal microbiota in rats with PO−induced hyperuricemia based on unweighted Jensen−Shannon distance measures of all samples based on OTU−level relative abundance profiles. Results are means for n = 3; # mean values are significantly different from control group (p < 0.05); * mean values are significantly different from HC group (p < 0.05) (Jensen−Shannon, genus, exclude unclassified OTU (reads)).
Nutrients 14 04832 g002
Nutrients 14 04832 g003 550
Figure 3. Effect of TCI227 on fecal microbiota phylum-level compositions in PO-induced hyperuricemia rats. The reported values are means (n = 3).
Figure 3. Effect of TCI227 on fecal microbiota phylum-level compositions in PO-induced hyperuricemia rats. The reported values are means (n = 3).
Nutrients 14 04832 g003
Nutrients 14 04832 g004 550
Figure 4. Effect of TCI227 on relative abundance of Deferribacteres in feces. The reported values are means ± SD (n = 3); # significantly differs from the HC group (p < 0.05); * significantly differs from the HC group (p < 0.05); ** significantly differs from the HC group (p < 0.01).
Figure 4. Effect of TCI227 on relative abundance of Deferribacteres in feces. The reported values are means ± SD (n = 3); # significantly differs from the HC group (p < 0.05); * significantly differs from the HC group (p < 0.05); ** significantly differs from the HC group (p < 0.01).
Nutrients 14 04832 g004
Nutrients 14 04832 g005 550
Figure 5. Effect of TCI227 on fecal microbiota family-level compositions in PO-induced hyperuricemia rats. The reported values are means (n = 3).
Figure 5. Effect of TCI227 on fecal microbiota family-level compositions in PO-induced hyperuricemia rats. The reported values are means (n = 3).
Nutrients 14 04832 g005
Nutrients 14 04832 g006 550
Figure 6. Effect of TCI227 on relative abundances of Prevotellaceae (A), Lactobacillaceae (B), and Deferribacteraceae (C) in feces. The reported values are means ± SD (n = 3); # significantly differs from the HC group (p < 0.05); * significantly differs from the HC group (p < 0.05); ** significantly differs from the HC group (p < 0.01).
Figure 6. Effect of TCI227 on relative abundances of Prevotellaceae (A), Lactobacillaceae (B), and Deferribacteraceae (C) in feces. The reported values are means ± SD (n = 3); # significantly differs from the HC group (p < 0.05); * significantly differs from the HC group (p < 0.05); ** significantly differs from the HC group (p < 0.01).
Nutrients 14 04832 g006
Nutrients 14 04832 g007 550
Figure 7. Effect of TCI227 on fecal microbiota genus-level compositions in PO-induced hyperuricemia rats. The reported values are means (n = 3).
Figure 7. Effect of TCI227 on fecal microbiota genus-level compositions in PO-induced hyperuricemia rats. The reported values are means (n = 3).
Nutrients 14 04832 g007
Nutrients 14 04832 g008 550
Figure 8. Effect of TCI227 on relative abundances of Prevotella (A), Lactobacillus (B), and Ruminococcus (C) in feces. The reported values are means ± SD (n = 3); # significantly differs from the HC group (p < 0.05); ## significantly differs from the HC group (p < 0.01); * significantly differs from the HC group (p < 0.05).
Figure 8. Effect of TCI227 on relative abundances of Prevotella (A), Lactobacillus (B), and Ruminococcus (C) in feces. The reported values are means ± SD (n = 3); # significantly differs from the HC group (p < 0.05); ## significantly differs from the HC group (p < 0.01); * significantly differs from the HC group (p < 0.05).
Nutrients 14 04832 g008
Table
Table 1. Effects of TCI227 on the initial body weight, final body weight, weight change, food intake, and water intake of potassium-oxonate (PO)-induced hyperuricemia SD rats.
Table 1. Effects of TCI227 on the initial body weight, final body weight, weight change, food intake, and water intake of potassium-oxonate (PO)-induced hyperuricemia SD rats.
GroupsControlHCHC + LDHC + MDHC + HDHC + AP
Initial body weight (g)280.20 ± 13.00292.94 ± 12.94294.65 ± 17.29294.30 ± 9.51286.70 ± 19.66287.20 ± 7.69
Final body weight (g)399.83 ± 36.07365.44 ± 21.92 #374.65 ± 13.55388.24 ± 18.49376.64 ± 25.09374.04 ± 19.52
Weight change (g)119.63 ± 24.6372.50 ± 10.70 ##80.00 ± 23.3293.94 ± 19.49 *89.94 ± 10.62 **86.84 ± 17.80
Food intake (g/rat/day)26.94 ± 0.8622.68 ± 1.20 ##25.12 ± 1.00 **24.97 ± 1.11 **24.45 ± 1.35 *23.35 ± 1.03
Water intake (mL/rat/day)45.66 ± 2.7042.41 ± 2.92 #44.97 ± 4.2042.44 ± 3.3450.69 ± 2.68 **47.43 ± 4.88 *
The reported values are means ± SD (n = 8); # significantly differs from the HC group (p < 0.05); ## significantly differs from the HC group (p < 0.01); * significantly differs from the HC group (p < 0.05); ** significantly differs from the HC group (p < 0.01). HC, hyperuricemia control; LD, low dose (108 CFU/kg rat); MD, medium dose (109 CFU/kg rat); HD, high dose (1010 CFU/kg rat); AP, allopurinol. Weight change (g) = final body weight (g)—initial body weight (g).
Table
Table 2. Effects of TCI227 on the weights of organs, adipose tissues, and muscle tissues in PO-induced hyperuricemia SD rats.
Table 2. Effects of TCI227 on the weights of organs, adipose tissues, and muscle tissues in PO-induced hyperuricemia SD rats.
Weight of Organs and Tissues
(mg/g rat)		ControlHCHC + LDHC + MDHC + HDHC + AP
Liver33.62 ± 1.7438.56 ± 1.57 ##38.29 ± 2.0738.79 ± 2.4737.08 ± 2.3337.06 ± 2.19
Heart3.53 ± 0.183.54 ± 0.263.58 ± 0.253.48 ± 0.303.49 ± 0.383.41 ± 0.23
Lung3.72 ± 0.323.99 ± 0.233.82 ± 0.373.83 ± 0.194.04 ± 0.194.05 ± 0.40
Spleen2.36 ± 0.925.66 ± 1.00 ##6.52 ± 0.815.78 ± 1.055.27 ± 1.145.52 ± 1.14
Kidney8.43 ± 1.008.51 ± 0.498.45 ± 0.649.00 ± 0.488.49 ± 0.898.11 ± 0.38
Epididymal adipose tissue8.89 ± 1.677.52 ± 1.648.51 ± 1.956.97 ± 1.497.83 ± 1.626.77 ± 3.16
Perirenal adipose tissue11.05 ± 3.047.52 ± 2.25 #8.87 ± 3.397.31 ± 1.588.02 ± 2.627.39 ± 1.46
Mesenteric adipose tissue6.00 ± 2.217.44 ± 2.6810.12 ± 2.8310.31 ± 5.759.05 ± 3.267.69 ± 2.21
Subcutaneous adipose tissue13.28 ± 2.9411.07 ± 2.9812.74 ± 3.3211.50 ± 1.9012.75 ± 1.949.44 ± 1.76
Brown adipose tissue0.64 ± 0.200.52 ± 0.100.45 ± 0.220.61 ± 0.280.49 ± 0.160.58 ± 0.17
Gastrocnemius muscle7.87 ± 2.839.21 ± 2.499.14 ± 2.678.71 ± 2.669.11 ± 2.859.16 ± 2.38
Soleus muscle0.92 ± 0.140.84 ± 0.080.84 ± 0.100.83 ± 0.110.90 ± 0.090.91 ± 0.07
The reported values are means ± SD (n = 8); # significantly differs from the HC group (p < 0.05); ## significantly differs from the HC group (p < 0.01).
Table
Table 3. Effects of TCI227 on serum biochemical parameters in PO-induced hyperuricemia SD rats.
Table 3. Effects of TCI227 on serum biochemical parameters in PO-induced hyperuricemia SD rats.
GroupsControlHCHC + LDHC + MDHC + HDHC + AP
Glucose (mg/dL)97.25 ± 9.9597.75 ± 12.9689.13 ± 5.7497.38 ± 19.0490.13 ± 8.5991.13 ± 10.88
Total cholesterol (mg/dL)44.88 ± 5.8746.00 ± 9.5944.75 ± 11.4648.88 ± 7.6248.38 ± 8.4540.63 ± 8.23
Triglyceride (mg/dL)83.75 ± 29.5050.88 ± 12.18 #45.00 ± 13.6643.75 ± 14.3242.38 ± 10.6837.50 ± 5.86 *
AST (U/L)75.50 ± 5.6377.25 ± 14.8393.88 ± 36.7669.63 ± 13.5477.75 ± 14.4473.63 ± 11.21
ALT (U/L)38.88 ± 6.8530.13 ± 9.3936.50 ± 6.3031.50 ± 8.8037.50 ± 15.8630.50 ± 8.77
BUN (mg/dL)14.38 ± 1.3014.13 ± 1.8914.38 ± 2.8813.25 ± 1.8314.75 ± 2.9216.50 ± 4.44
Creatinine (mg/dL)0.35 ± 0.050.34 ± 0.040.32 ± 0.060.28 ± 0.03 **0.31 ± 0.030.34 ± 0.05
Na+ (mmol/L)145.25 ± 1.67141.75 ± 1.75 ##142.38 ± 1.06141.25 ± 1.58141.38 ± 2.20144.00 ± 1.85
K+ (mmol/L)6.36 ± 0.176.64 ± 0.676.84 ± 0.716.84 ± 0.456.74 ± 1.016.48 ± 0.50
Cl− (mmol/L)96.76 ± 1.3899.05 ± 2.71 #99.45 ± 2.4198.49 ± 1.3998.70 ± 1.93100.15 ± 0.98
The reported values are means ± SD (n = 8); # significantly differs from the HC group (p < 0.05); ## significantly differs from the HC group (p < 0.01); * significantly differs from the HC group (p < 0.05); ** significantly differs from the HC group (p < 0.01).
Table
Table 4. Effects of TCI227 on serum uric acid and urine uric acid in PO-induced hyperuricemia SD rats.
Table 4. Effects of TCI227 on serum uric acid and urine uric acid in PO-induced hyperuricemia SD rats.
GroupsControlHCHC + LDHC + MDHC + HDHC + AP
Serum uric acid (mg/dL)
Week 04.05 ± 1.704.41 ± 1.714.11 ± 2.464.04 ± 2.774.08 ± 1.684.27 ± 2.25
Week 44.83 ± 0.706.52 ± 0.91 ##4.96 ± 1.77 *5.16 ± 1.54 *5.22 ± 1.801.32 ± 0.76 **
Urine uric acid (mg/dL)
Week 07.41 ± 3.037.68 ± 3.286.55 ± 0.547.70 ± 2.817.86 ± 3.537.64 ± 2.53
Week 26.66 ± 1.783.14 ± 2.22 ##4.48 ± 2.515.21 ± 2.86 **5.59 ± 2.783.23 ± 1.61
Week 46.39 ± 1.423.91 ± 1.71 ##6.08 ± 1.72 *5.41 ± 0.72 *5.15 ± 0.694.71 ± 1.67
The reported values are means ± SD (n = 8); ## significantly differs from the HC group (p < 0.01); * significantly differs from the HC group (p < 0.05); ** significantly differs from the HC group (p < 0.01).
Table
Table 5. Effects of TCI227 on fecal short-chain fatty acids (SCFAs) in PO-induced hyperuricemia SD rats.
Table 5. Effects of TCI227 on fecal short-chain fatty acids (SCFAs) in PO-induced hyperuricemia SD rats.
GroupsControlHCHC + LDHC + MDHC + HDHC + AP
Acetic acid (μmol/g)8.22 ± 1.735.21 ± 0.50 ##7.17 ± 2.315.56 ± 1.715.34 ± 0.604.67 ± 1.23
Propionic acid (μmol/g)2.62 ± 0.981.79 ± 0.432.30 ± 0.771.97 ± 0.701.97 ± 0.221.84 ± 0.52
Butyric acid (μmol/g)8.60 ± 4.384.14 ± 1.29 #5.41 ± 1.805.68 ± 5.304.34 ± 1.184.69 ± 3.46
Valeric acid (μmol/g)0.77 ± 0.210.50 ± 0.12 #0.50 ± 0.150.55 ± 0.200.51 ± 0.040.46 ± 0.13
The reported values are means ± SD (n = 6); # significantly differs from the HC group (p < 0.05); ## significantly differs from the HC group (p < 0.01).
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Chien, C.-Y.; Chien, Y.-J.; Lin, Y.-H.; Lin, Y.-H.; Chan, S.-T.; Hu, W.-C.; Wu, H.-F.; Chiang, C.-F.; Hsu, C.-L. Supplementation of Lactobacillus plantarum (TCI227) Prevented Potassium-Oxonate-Induced Hyperuricemia in Rats. Nutrients 2022, 14, 4832. https://doi.org/10.3390/nu14224832

AMA Style

Chien C-Y, Chien Y-J, Lin Y-H, Lin Y-H, Chan S-T, Hu W-C, Wu H-F, Chiang C-F, Hsu C-L. Supplementation of Lactobacillus plantarum (TCI227) Prevented Potassium-Oxonate-Induced Hyperuricemia in Rats. Nutrients. 2022; 14(22):4832. https://doi.org/10.3390/nu14224832

Chicago/Turabian Style

Chien, Chih-Yu, Yu-Jou Chien, Yung-Hao Lin, Yung-Hsiang Lin, Shu-Ting Chan, Wei-Chun Hu, Han-Fang Wu, Chi-Fu Chiang, and Chin-Lin Hsu. 2022. "Supplementation of Lactobacillus plantarum (TCI227) Prevented Potassium-Oxonate-Induced Hyperuricemia in Rats" Nutrients 14, no. 22: 4832. https://doi.org/10.3390/nu14224832

APA Style

Chien, C. -Y., Chien, Y. -J., Lin, Y. -H., Lin, Y. -H., Chan, S. -T., Hu, W. -C., Wu, H. -F., Chiang, C. -F., & Hsu, C. -L. (2022). Supplementation of Lactobacillus plantarum (TCI227) Prevented Potassium-Oxonate-Induced Hyperuricemia in Rats. Nutrients, 14(22), 4832. https://doi.org/10.3390/nu14224832

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop